The University of Chicago Header Logo

Connection

Septimiu Murgu to Ipilimumab

Back to Details
This is a "connection" page, showing publications Septimiu Murgu has written about Ipilimumab.
Septimiu Murgu
Connection Strength
0.048
Ipilimumab
  1. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.